PEAK PROCESSING LIMITED — Regulatory Filings 2019

Jun 24, 2019

ASX Announcement | 25 June 2019 Althea Group Holdings (ASX:AGH)

Althea to Supply First UK National Medical Cannabis Pilot Targeting 20,000 Patients

Investment Highlights:

• The Drug Science Medical Cannabis Working Group, which includes the United Patients Alliance, is launching the UK's first national pilot for medical cannabis
• The pilot aims to enrol 20,000 patients before the end of 2021 and will use a real word data patient registry to assess efficacy, safety and patient-reported outcomes in patients prescribed medical cannabis
• Althea has been selected from a limited number of medicinal cannabis companies, to supply its range of products to the pilot

25 June 2019: Australian medicinal cannabis company Althea Group Holdings Limited (ASX: AGH) through its wholly-owned subsidiary Althea MMJ UK Ltd ('Althea' or 'the Company'), is pleased to announce that it has furthered its relationship with independent scientific committee Drug Science with the goal of increasing the number of patients that can be prescribed medical cannabis in the UK.

Drug Science's "Project TWENTY21" ('the Pilot') is the UK's first national pilot for medical cannabis. Project TWENTY21 will be officially launched on 18th July 2019 and aims to enrol 20,000 patients before the end of 2021. Althea has been selected from a limited number of medicinal cannabis companies to supply, on commercial terms, its range of products to the Pilot.

In the first instance, Project TWENTY21 will be targeting patients including those in the following categories, specifically focusing on patients in which alternative treatment has failed:

• Chronic pain
• PTSD, with a focus on the veteran community
• Anxiety
• Multiple sclerosis
• Tourette's syndrome

It is intended that Project TWENTY21 will develop a body of evidence using a realworld data registry which documents the efficacy, safety, quality-adjusted life year (QALY) and patient-reported outcomes of medical cannabis use.

This data will then be used to support applications to health authorities in the expectation that there will soon be a new regulatory system for medical cannabis in the UK.

Patient treatment and monitoring will be administered by doctors based in My Cannabis Access Clinics in multiple locations across the UK including London, Bristol and Glasgow.

Potential UK patients will be able to register their interest in participating in the Pilot, which is scheduled to commence in Q4 CY19, via www.mycannabisaccess.com.

Althea's participation in Drug Science's working group and subsequent inclusion in Project TWENTY21 is part of the Company's proven education-backed patient focussed strategy and further enhances its European and global reputation.

Althea Chief Medical Officer Dr Robert Pawinski said: "Althea is proud to be able to provide our medicinal cannabis as part of the national pilot, and resources to ensure patient access. We believe the pilot program will yield valuable data that can then be used to further bolster the case for wider medicinal cannabis use and inform public health and stakeholder decisions."

Drug Science Chief Scientific Officer and Chair of the Scientific Committee Prof David Nutt said: "…Drug Science has joined forces with the United Patients Alliance [the UK's first medicinal cannabis support group], leading academics and several medical cannabis producers to open up a treatment network for up to 20,000 patients. This will allow patients to get vital therapy without breaking the law. It will also provide a solid clinical database from which experience of and confidence in, medical cannabis prescribing will develop, providing a foundation for other medical prescribers to build on."

United Patient Alliance Director and Founder Clarke French said: "The United Patient Alliance is delighted to partner with Drug Science on Project TWENTY21. We believe it is a vital initiative. Patients in the United Kingdom deserve evidence-based policy and access to cannabis medicines on the NHS. Project TWENTY21 will provide a growing body of evidence, to enable cannabis medicines to be accessed by the patients who desperately need it.

-ENDS-

For further information, please contact:

Josh Fegan Julia Maguire CEO & Managing Director The Capital Network M: 1300 70 20 20 M: +61 419 815 386

Althea Media Enquiries

E: contact@althea.life E: julia@thecapitalnetwork.com.au

Australian Investors

PAC Partners Securities M: 03 8633 9834 E: enquiries@pacpartners.com.au

Althea Group Holdings Limited (ASX:AGH)

Althea is an Australian licensed producer, supplier and exporter of pharmaceutical grade medicinal cannabis and is listed publicly on the Australian Securities Exchange (ASX:AGH). Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.

Althea currently operates within highly regulated medicinal cannabis markets including Australia and the United Kingdom, with plans to expand into emerging markets throughout Asia and Europe.

To learn more, please visit: www.althea.life

Drug Science

Founded in 2010 by Professor David Nutt, Drug Science is the only completely independent, science-led drugs charity, uniquely bringing together leading drugs experts from a wide range of specialisms to carry out ground-breaking original research into drug harms and effects.

Its highly cited papers on all aspects of drug effects and harms attract global coverage and considerable public interest. Drug Science reduces the harms of drugs to the public through providing objective information on drug effects, harms and potential medical uses to the public, professionals and decision makers.

To learn more, please visit: www.drugscience.org.uk

United Patients Alliance (UPA)

Founded in 2014, the UPA is the UK's first medical cannabis support group, run by patients, for patients; United Patients Alliance provide tireless advocacy, compassionate campaigning, and essential education, to safeguard the patients' voice in advancing legal access to cannabis therapeutics.

To learn more, please visit: www.upalliance.org